Labcorp Holdings Inc.
LHDiagnostics & Research
$361.39−1.84%As of Oct 30vs prior close
- Market cap
- $29.3B
- P/E (TTM)
- 29.4×
- P/E (FY1)
- 19.6×
- From 52W high
- −1.84%
- EPS (LTM)
- $12.19
- Revenue (LTM)
- $14.6B
- Net margin
- 6.88%
- Dividend yield
- 0.80%
Nomior Score
67
Steady ProfileTop 14% of the scored universe
Growth39
Quality58
Value77
Momentum73
Resilience57
Growth
+4.30%revenue a year over 9 fiscal years
FY16 $9.6BLTM $14.6B
Connections
Revenue to profitQ3 FY26
7% of revenue became net profit.
Latest resultsthird quarter 2026
- Diluted EPS
- $3.22
- Adjusted EPS
- $4.78
Labcorp reported higher revenue and adjusted earnings per share for the quarter, with growth coming from organic sales and acquisitions. Specialty testing and Biopharma Laboratory Services were key contributors, and operating margins improved. The company raised its full-year revenue growth and adjusted EPS guidance and announced several acquisitions and product launches.
Who owns it
6funds, 3 tracked portfolios